MicroPort, a Shanghai medical device company, co-led a $20 million Series C financing in Rapid Medical, an Israeli company developing a stentreiver treatment for stroke. As part of the agreement, MicroPort will partner with Rapid Medical to develop the treatment in China. Rapid Medical said it would use the funding to complete a US IDE study and support the commercial growth of the stroke treatment globally. The C round was co-led by JAM Capital Partners with participation from Agate JT, RocSon Medtech Fund and existing investors.
Source: China Biotoday
